
Switch Therapeutics: Pioneering RNAi therapies and nucleic acid nanotechnology for diverse disease treatment.
Switch Therapeutics, founded with a mission to revolutionize RNA interference (RNAi) therapies, focuses on integrating nucleic acid nanotechnology to treat a variety of diseases, particularly those affecting the central nervous system. The company's core product is its proprietary Conditionally Activated siRNA (CASi) platform, which combines the advantageous properties of single and double-stranded RNA into a single molecule, enabling efficient self-delivery and targeted treatment.
Notable affiliates include leading scientists and industry experts in RNAi and nanotechnology. The company has garnered attention from prominent investors in the biotech sector, reflecting confidence in its innovative approach. Key achievements include significant advancements in their CASi platform, positioning Switch Therapeutics as a transformative player in genetic medicine. Their impact lies in potentially offering groundbreaking treatments for previously challenging medical conditions.

Traversa Therapeutics
traversathera.com

Sirius Therapeutics
siriusrna.com

Wayfinder Biosciences
wayfinderbio.com

Atalanta Therapeutics
atalantatx.com

Silence Therapeutics

Nextrna Therapeutics

Sirnaomics
sirnaomics.com

ReviR Therapeutics
revirtx.com

Kylin Therapeutics

Sixfold Bioscience
sixfold.bio

ReNAgade Therapeutics

Alnylam Pharmaceuticals aln
alnylam.com

Innovac Therapeutics
innovactx.com

Shape Therapeutics
shapetx.com

Flashpoint Therapeutics
flashpoint.bio
Companies similar to Switch Therapeutics include Traversa Therapeutics, Sirius Therapeutics, Wayfinder Biosciences and Atalanta Therapeutics.
Switch Therapeutics was founded in 2020.
Switch Therapeutics' headquarters is located in San Francisco, CA, US.
Switch Therapeutics' most recent funding round was for $52M (USD) in March 2023.
As of Mar 14, 2023, Switch Therapeutics has raised a total of $52M (USD).
Switch Therapeutics has 16 employees as of Feb 5, 2024.